MLTX INVESTOR ALERT: MoonLake Immunotherapeutics (MLTX) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate

Core Viewpoint - A securities class action has been filed against MoonLake Immunotherapeutics following the announcement of poor Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price [1][2]. Company Overview - MoonLake Immunotherapeutics is a clinical stage biotechnology company focused on treating skin inflammatory diseases, specifically targeting cytokines IL-17A and IL-17F [3][4]. Trial Results and Market Reaction - The Phase 3 trial results revealed that only one of the two trials achieved statistical significance, with efficacy substantially lower than that of a competitor's product, BIMZELX [6]. - Following the announcement, MoonLake's share price plummeted by $55.75, approximately 90%, on September 29, 2025 [2][6]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK over BIMZELX [5][6]. - Specific allegations include misleading claims about the clinical benefits of SLK's Nanobody structure compared to traditional monoclonal antibodies [5]. Legal Proceedings - The class action lawsuit is focused on the accuracy of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3][4]. - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3].